一年两次来那卡韦：非洲年轻女性预防艾滋病的里程碑。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-10-11 DOI:10.1016/j.medj.2024.08.008

Silvia Nozza, Antonella Castagna

引用次数: 0

摘要

PURPOSE 1试验1表明，52周后，接受一年两次来那卡韦皮下注射的顺性别女性中没有人感染艾滋病毒。来那卡韦的HIV感染率明显低于每日口服恩曲他滨/替诺福韦阿拉非酰胺（F/TAF）或每日口服恩曲他滨/富马酸替诺福韦二吡呋酯（F/TDF）。这是首个对年轻女性具有 100% 有效率的暴露前预防方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Twice-yearly lenacapavir: A milestone for HIV prevention in young African women.

The PURPOSE 1 trial¹ demonstrated that after 52 weeks, no cisgender women acquired HIV infection after receiving subcutaneous twice-yearly lenacapavir. HIV incidence with lenacapavir was significantly lower than HIV incidence with daily oral emtricitabine/tenofovir alafenamide (F/TAF) or daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). It is the first pre-exposure prophylaxis regimen with 100% efficacy in young women.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.